These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 9608317

  • 41. [Immunosuppressive therapy of systemic lupus erythematosus].
    Miescher PA, Lambert PH.
    Ther Umsch; 1971 Sep; 28(9):579-85. PubMed ID: 5122520
    [No Abstract] [Full Text] [Related]

  • 42. [Drug alternatives in therapy of neuropsychiatric systemic lupus erythematosus (NPSLE)].
    Harten P.
    Med Klin (Munich); 2003 Jun 15; 98(6):344; author reply 344-5. PubMed ID: 12877108
    [No Abstract] [Full Text] [Related]

  • 43. Successful treatment of class IV+V lupus nephritis with combination therapy of high-dose corticosteroids, tacrolimus and intravenous cyclophosphamide.
    Kurasawa T, Nagasawa H, Nishi E, Takei H, Okuyama A, Kondo T, Nishimura K, Sakai R, Shibata A, Chino K, Ogawa H, Ito T, Amano K, Kato H.
    Intern Med; 2013 Jun 15; 52(10):1125-30. PubMed ID: 23676603
    [Abstract] [Full Text] [Related]

  • 44. Therapeutics. XI. Immunosuppressive drugs.
    Ashton H, Beveridge GW, Stevenson CJ.
    Br J Dermatol; 1970 Aug 15; 83(2):326-30. PubMed ID: 4916789
    [No Abstract] [Full Text] [Related]

  • 45. Immunosuppressive agents in dermatology. An update.
    Dutz JP, Ho VC.
    Dermatol Clin; 1998 Apr 15; 16(2):235-51. PubMed ID: 9589197
    [Abstract] [Full Text] [Related]

  • 46. Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study.
    Mok CC, Lau CS, Wong RW.
    Am J Med; 2003 Jul 15; 115(1):59-62. PubMed ID: 12867236
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. [The immunosuppressive agents. 3. The immunosuppressive agents in hematology].
    Meshaka G, Jacquillat C, Sultan Y.
    Presse Med (1893); 1967 Jul 01; 75(32):1653-5. PubMed ID: 6067478
    [No Abstract] [Full Text] [Related]

  • 49. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
    Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senécal JL, Cividino A, Danoff D, Osterland CK, Yeadon C, Smith CD.
    Lupus; 1998 Jul 01; 7(2):80-5. PubMed ID: 9541091
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. [Systemic treatment of cutaneous lupus erythematosus].
    Wenzel J, Bieber T, Uerlich M, Tüting T.
    J Dtsch Dermatol Ges; 2003 Sep 01; 1(9):694-704. PubMed ID: 16285276
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Evidence-based evaluation of immunomodulatory therapy for the cutaneous manifestations of lupus.
    Heath M, Raugi GJ.
    Adv Dermatol; 2004 Sep 01; 20():257-91. PubMed ID: 15544204
    [Abstract] [Full Text] [Related]

  • 54. Thalidomide: focus on its employment in rheumatologic diseases.
    Ossandon A, Cassarà EA, Priori R, Valesini G.
    Clin Exp Rheumatol; 2002 Sep 01; 20(5):709-18. PubMed ID: 12412207
    [Abstract] [Full Text] [Related]

  • 55. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate.
    Sandborn WJ.
    Am J Gastroenterol; 1996 Mar 01; 91(3):423-33. PubMed ID: 8633486
    [No Abstract] [Full Text] [Related]

  • 56. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis: update.
    Santana AN, Woronik V, Halpern AS, Barbas CS.
    J Bras Pneumol; 2011 Mar 01; 37(6):809-16. PubMed ID: 22241040
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine.
    Laaksonen AL, Koskiahde V, Juva K.
    Scand J Rheumatol; 1974 Mar 01; 3(2):103-8. PubMed ID: 4608161
    [No Abstract] [Full Text] [Related]

  • 60. Cyclosporine in the treatment of autoimmune disorders: a 10-year experience.
    Mitrovic D, Popovic M, Glisic B, Pavlica L, Dimitrijevic M.
    Transplant Proc; 1998 Dec 01; 30(8):4134. PubMed ID: 9865324
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.